Table 1.
Year |
Country & Site |
Laboratory | Method used | N |
Unresolved by PCR n |
Resolved by PCR n |
PCR Use- effectiveness [95%CI] |
recurr. after day14 |
|||||||
2002 | Zambia, Maheba | Rouen France | msp2 | 43 | 3 | 40 | 93.0 |
[80.9–98.5] | |||||||
2003 | Angola, Kuito | IMT Antwerp | msp1+msp2 | 8 | 0 | 8 | 100.0 |
[63.1–100.0] | |||||||
2003 | DRC, Boende | IMT Antwerp | msp1+msp2 +glurp | 78 | 10 | 68 | 87.2 |
[77.7–93.7] | |||||||
2003 | S Sudan, Nuba | Wellcome Trust/Medical College of Malawi | msp1+msp2 | 54 | 15 | 39 | 72.2 |
[58.3–83.5] | |||||||
2003 | Uganda, Amudat | Epicentre Mbarara | msp1+msp2 +glurp | 73 | 4 | 69 | 94.5 |
[86.6–98.5] | |||||||
2003 | Uganda, Jinja | UCSF | msp2 | 27 | 2 | 25 | 92.6 |
[75.7–99.1] | |||||||
2003 | Uganda, Kampala | UCSF | msp2 | 14 | 0 | 14 | 100.0 |
[76.8–100.0]* | |||||||
2004 | Angola, Caala | Mbarara University | msp1+msp2 +glurp | 6 | 2 | 4 | 66.7 |
[22.3–95.7] | |||||||
2004 | Congo, Kindamba | SMRU | msp1+msp2 +glurp | 60 | 24 | 36 | 60.0 |
[46.5–72.4] | |||||||
2004 | DRC, Kabalo | Epicentre Mbarara | msp1+msp2 +glurp | 10 | 1 | 9 | 90.0 |
[55.5–99.7] | |||||||
2004 | Guinea, Dabola | Epicentre Mbarara | msp1+msp2 +glurp | 14 | 1 | 13 | 92.9 |
[66.1–99.8] | |||||||
2004 | Sierra Leone, Kailahun | Paris, Avicenne | msp1+msp2 | 65 | 1 | 64 | 98.5 |
[91.7–100.0] | |||||||
2004 | Uganda, Apac | UCSF | msp2 | 76 | 3 | 73 | 96.0 |
[88.9–99.2] | |||||||
2004 | Uganda, Arua | UCSF | msp2 | 61 | 4 | 57 | 93.4 |
[84.1–98.2] | |||||||
2004 | Uganda, Tororo | UCSF | msp2 | 120 | 3 | 117 | 97.5 |
[92.9–99.5] | |||||||
2005 | Burkina Faso, Bobo-Dioulasso | UCSF | msp1 +msp2 + 4 microsatellites | 24 | 0 | 24 | 100 |
[85.7–100]* | |||||||
2005 | Uganda, Tororo | UCSF | msp1+msp2 | 209 | 4 | 205 | 98.1 |
[95.2–99.5] | |||||||
TOTAL | 942 | 77 | 865 | ||||
Weighted average [CI 95] | 91.8 [89.9–93.4] | ||||||
Median [range] | 93.4 [60–100] |
Use-effectiveness = number of children with parasite recurrence resolved by PCR/total number of children with recurrences after day 14.
* One sided 97.5% CIs have been calculated
IMT Institut de Médecine Tropicale Antwerp
KEMRI Kenya Medical Research Institute
SMRU Shoklo Malaria Research Unit, Thailand
UCSF University of California, San Francisco
msp1 merozoite surface protein 1
msp2 merozoite surface protein 2
glurp glutamate rich protein